Lupin Ltd.
Research Lupin Ltd. (LUPIN.NS) on Bullrun: market cap INR 897.02B, P/E 16.2, dividend yield 0.9%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerLUPIN.NS
- ExchangeNSE
- CountryIndia
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyINR
- Market capINR 897.02B
- P/E16.2
- Dividend yield0.9%
- Financial periodQ2 2026
- RevenueINR 82.17B
- Net incomeINR 14.15B
- Gross margin74.6%
Valuation Snapshot
latest market cap is INR 897.02B; P/E is 16.2; dividend yield is 0.9%.
Peer valuation comparison
Latest P/E is 16.25x versus a Healthcare sector median of 21.74x (25.3% below).
Latest dividend yield is 0.92% versus a Healthcare sector median of 2.4% (61.7% below).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | INR 897.02B | 16.2 | 0.9% | 18 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 18 INR, yield 0.9%.
About Lupin Ltd.
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It produces, develops, and markets various branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs).
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Lupin Ltd.'s market cap?
Lupin Ltd.'s market capitalization is INR 897.02B.
What is Lupin Ltd.'s P/E ratio?
Lupin Ltd.'s price-to-earnings (P/E) ratio is 16.2.
Does Lupin Ltd. pay a dividend?
Lupin Ltd. has a dividend yield of 0.9%.
What does Lupin Ltd. do?
Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India, the United States, and internationally. The company operates in two segments: Pharmaceuticals and Others. It produces, develops, and markets various branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The company also offers products in the therapeutic areas of cardiovascular, diabetology, asthama, pediatrics, central nervous system, gastro-intestinal, anti-infectives, anti-TB, cephalosporins, and nonsteroidal anti-inflammatory drug therapies.